WisdomTree Launches BioRevolution Fund (WDNA)
WisdomTree Investments, Inc. (NASDAQ: WETF) has launched the WisdomTree BioRevolution Fund (WDNA) on the CBOE, aimed at tracking the WisdomTree BioRevolution Index. This ETF has an expense ratio of 0.45% and seeks to tap into investments in companies transformed by advancements in genetics and biotechnology, including sectors like healthcare, agriculture, and energy. WisdomTree collaborated with futurist Dr. Jamie Metzl to identify key sectors for investment. The fund highlights significant investment opportunities amid the biological revolution, reflecting a commitment to innovative investment strategies.
- Launch of WisdomTree BioRevolution Fund (WDNA) aimed at capturing growth in genetics and biotechnology.
- Expense ratio of 0.45% is competitive for an ETF.
- Collaboration with Dr. Jamie Metzl adds credibility and expertise to investment themes.
- Focus on diverse sectors including healthcare, agriculture, and energy indicates potential growth.
- Investing in BioRevolution companies may face intense competition and rapid product obsolescence.
- Risks associated with loss of intellectual property rights and changes in government regulations.
- The fund does not seek to outperform its index, potentially limiting returns.
WDNA offers targeted exposure to companies that will be significantly transformed by advancements in genetics and biotechnology, including COVID-19 vaccines
WisdomTree leveraged data and thematic insights from one of the world’s leading technology futurists Dr. Jamie Metzl
NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- WisdomTree Investments, Inc. (NASDAQ: WETF), an exchange-traded fund (“ETF”) and exchange-traded product (“ETP”) sponsor and asset manager, announced today the launch of the WisdomTree BioRevolution Fund (WDNA) on the CBOE. WDNA seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (WTDNA), and has an expense ratio of
“The biology revolution is creating a historic investment opportunity equivalent to the industrial and internet revolutions,” said Jeremy Schwartz, Global Head of Research at WisdomTree. “The WisdomTree BioRevolution Fund offers diversified exposure to a basket of companies that we believe is uniquely positioned to seize the opportunity at the intersection of biology and technology. This launch represents the latest in our ongoing commitment to offering investors innovative investment opportunities.”
WisdomTree leveraged data from Dr. Jamie Metzl, one of the world’s leading technology futurists1 and Special Strategist for WisdomTree, in its construction of the WisdomTree BioRevolution Index, which identifies the key sectors and industries that are expected to be most significantly transformed by advances in biological science and technology.
“The genetics and biotechnology revolutions won’t just change our healthcare systems, allowing us to live healthier and longer lives,” explained Dr. Jamie Metzl, author of Hacking Darwin: Genetic Engineering and the Future of Humanity. “They will also fundamentally transform our world far beyond healthcare. The same technologies driving healthcare innovation will have a seismic impact on industries including agriculture, materials, energy, and information processing, revolutionizing the ways we treat disease, grow food, produce materials, and process data. If the nineteenth was the century of chemistry and the twentieth of physics, the twenty-first will be the century of biology. I am delighted to be collaborating with the amazing team at WisdomTree in uncovering the massive opportunities of this historic megatrend.”
WDNA: What’s Under the Hood?
The WisdomTree BioRevolution Fund merges both qualitative and quantitative evaluations of eligible stocks in an effort to identify a portfolio of best-in-class companies working at the forefront of these biological breakthroughs through the following themes:
- Human Health: The application of genetic technologies to prevent and treat diseases will lead to significant enhancements to human health, well-being and longevity, with vaccine development being a top example.
- Agriculture & Food: The genetics and biotechnology revolutions will increasingly transform agriculture, aquaculture, and food production, creating healthier and more sustainable models for feeding the growing population.
- Materials, Chemicals, & Energy: Biological reengineering will be used to produce an increasing percentage of the physical inputs needed for manufacturing.
- Biological Machines & Interfaces: DNA has approximately one million times greater storage capacity than hard-disk storage and has the potential to revolutionize data storage.
Investors should carefully consider the investment objectives, risks, charges and expenses of the Fund before investing. To obtain a prospectus containing this and other important information, call 866.909.9473 or visit wisdomtree.com. Read the prospectus carefully before you invest.
There are risks associated with investing, including possible loss of principal.
The Fund invests in BioRevolution companies, which are companies significantly transformed by advancements in genetics and biotechnology. BioRevolution companies face intense competition and potentially rapid product obsolescence. These companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations or policies. Additionally, BioRevolution companies may be subject to risks associated with genetic analysis. The Fund invests in the securities included in, or representative of, its Index regardless of their investment merit and the Fund does not attempt to outperform its Index or take defensive positions in declining markets. The composition of the Index is governed by an Index Committee and the Index may not perform as intended. Please read the Fund’s prospectus for specific details regarding the Fund’s risk profile.
Statements concerning trends in the fields, industries and sectors discussed are based on current conditions, which will fluctuate. This material represents an assessment of trends discussed at a specific time and is not intended to be a forecast of future events or a guarantee of future results. This
material should not be relied upon as research or investment advice. The user of this information assumes the entire risk of any use made of the information provided herein.
WisdomTree Funds are distributed by Foreside Fund Services LLC, in the U.S. only. Foreside Fund Services LLC is not affiliated with the other entities mentioned.
Jeremy Schwartz is a registered representative of Foreside Fund Services, LLC.
1 Technology futurist: One who studies or predicts the future based on current trends in technology
WTPR-20210527-0120
About WisdomTree
WisdomTree Investments, Inc., through its subsidiaries in the U.S. and Europe (collectively, “WisdomTree”), is an exchange-traded fund (“ETF”) and exchange-traded product (“ETP”) sponsor and asset manager headquartered in New York. WisdomTree offers products covering equities, commodities, fixed income, leveraged and inverse, currencies, and alternative strategies. WisdomTree currently has approximately
WisdomTree® is the marketing name for WisdomTree Investments, Inc. and its subsidiaries worldwide.
Contact Information:
Media Relations
WisdomTree Investments, Inc.
Jessica Zaloom
+1.917.267.3735
Jzaloom@wisdomtree.com / wisdomtree@fullyvested.com
FAQ
What is the WisdomTree BioRevolution Fund (WDNA)?
What are the key sectors targeted by WDNA?
What is the expense ratio of the WisdomTree BioRevolution Fund?
Who collaborated with WisdomTree on the BioRevolution Index?
What risks are associated with investing in the WDNA fund?
